Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2018-05-18 Major Shareholding Noti…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage by a specific holder ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension') crossing a threshold ('Limit for number of shares 10 %'). It explicitly states the 'Reason for major shareholding notification New share issue' and provides the resulting distribution of total holdings, including the new share count (10,850,100) and percentage (11.85%). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2018-05-18 English
Rättelse: Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document text is titled "Rättelse: Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)" (Correction: Decisions at the Annual General Meeting in NeuroVive Pharmaceutical AB (publ)) and details the resolutions passed at the AGM held on April 27, 2018. Key decisions mentioned include the approval of the 2017 financial statements, decisions on dividend (none), election/re-election of board members and setting their remuneration, approval of remuneration guidelines for senior management, and granting authorization for future share issues. These topics are central to an Annual General Meeting (AGM). Since the document reports the *decisions* made at the meeting, it aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM.
2018-04-27 Swedish
Amendment: Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document explicitly states it is an 'Amendment: Resolutions from Annual General Meeting' and details the outcomes of the 'Annual General Meeting (AGM)' held on April 27, 2018. It covers resolutions regarding profit/loss approval, dividend, board member fees and elections, remuneration guidelines, and authorization for share issues, which are all typical components of AGM proceedings. This directly maps to the AGM Information category.
2018-04-27 English
NeuroVive offentliggör tilläggsprospekt
Report Publication Announcement Classification · 1% confidence The document is a press release titled "NeuroVive offentliggör tilläggsprospekt" (NeuroVive publishes supplementary prospectus). It explicitly states that the supplementary prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on several websites. This document is an announcement about the publication and registration of a financial document (a prospectus supplement related to a rights issue/offering), rather than the prospectus itself or a general regulatory filing. According to Rule 2, when a document announces the publication of a report/document, it should be classified as a Report Publication Announcement (RPA). The content is short and serves primarily to inform the public about the availability of the prospectus supplement, fitting the RPA definition.
2018-04-20 Swedish
NeuroVive publishes supplementary prospectus
Report Publication Announcement Classification · 1% confidence The document is titled "NeuroVive publishes supplementary prospectus" and explicitly states that a supplementary prospectus has been established and registered following a previous prospectus related to an offer to subscribe for Units. This document is an announcement about the availability and registration of a legal/financial document (the prospectus supplement) and includes restrictions on distribution. Since it is announcing the publication of a specific financial/offering document rather than being the full report itself (like a 10-K or IR), and it is a formal announcement, it fits best under the category for announcing the publication of reports. The most appropriate code is RPA (Report Publication Announcement). Although it relates to a capital raising/offering, the core action described is the publication/registration of the prospectus document itself.
2018-04-20 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding, specifically a 'Sell' transaction, by a major holder ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension'). It explicitly states the 'Reason for major shareholding notification' and provides the resulting share quantity and percentage (9.84%). This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized under the code MRQ.
2018-04-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.